Journal of Hepatology
Volume 49, Issue 6 , Pages 892-898 , December 2008

Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV–HCV co-infected patients on HCV therapy

  • Lionel Piroth

      Affiliations

    • Service des Maladies Infectieuses, CHU Dijon, 10, Boulevard du Maréchal de Lattre de Tassigny, 21079 DIJON Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 80 29 33 05; fax: +33 3 80 29 36 38.
    • ,
  • Fabrice Carrat

      Affiliations

    • Inserm U707, Faculté de Médecine Saint Antoine, Paris, France
    • ,
  • Sylvie Larrat

      Affiliations

    • Laboratoire de Virologie, CHU Grenoble, France
    • ,
  • Isabelle Goderel

      Affiliations

    • Inserm U707, Faculté de Médecine Saint Antoine, Paris, France
    • ,
  • Benoit Martha

      Affiliations

    • Service des Maladies Infectieuses, CHU Dijon, 10, Boulevard du Maréchal de Lattre de Tassigny, 21079 DIJON Cedex, France
    • ,
  • Christopher Payan

      Affiliations

    • Département de Microbiologie, CHU Brest, France
    • ,
  • Françoise Lunel-Fabiani

      Affiliations

    • Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU Angers, France
    • ,
  • Firouze Bani-Sadr

      Affiliations

    • Inserm U707, Faculté de Médecine Saint Antoine, Paris, France
    • Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, AP-HP, Paris, France
    • ,
  • Christian Perronne

      Affiliations

    • Service des Maladies Infectieuses et Tropicales, Hôpital Raymond Poincaré, AP-HP, Paris, France
    • ,
  • Patrice Cacoub

      Affiliations

    • Service de Médecine Interne, Hôpital Pitié-Salpétrière, Paris, AP-HP, France
    • ,
  • Stanislas Pol

      Affiliations

    • Service d’Hépatologie, Hôpital Cochin, AP-HP, Paris, France
    • ,
  • Patrice Morand

      Affiliations

    • Laboratoire de Virologie, CHU Grenoble, France

Received 29 May 2008 ,Revised 10 June 2008 ,Accepted 10 June 2008.

References 

  1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  2. Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459
  3. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848
  4. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–982
  5. Kojima H, Kaita KD, Zhang M, Giulivi A, Minuk GY. Genomic analysis of a recently identified virus (SEN virus) and genotypes D and H by polymerase chain reaction. Antiviral Res. 2003;60:27–33
  6. Sagir A, Kirschberg O, Heintges T, Erhardt A, Haussinger D. SEN virus infection. Rev Med Virol. 2004;14:141–148
  7. Jones JF, Kulkarni PS, Butera ST, Reeves WC. GB virus-C – a virus without a disease: we cannot give it chronic fatigue syndrome. BMC Infect Dis. 2005;5:78
  8. Chen S, Kao C, Chen C, Shih C, Hsu M, Chao C, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278:591–607
  9. Wagner A, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, et al. Serological pattern ’anti-hepatitis B core alone’ in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS. 2004;18:569–571
  10. Neau D, Winnock M, Jouvencel A, Faure M, Castera L, Legrand E, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002–2003. Clin Infect Dis. 2005;40:750–753
  11. Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, Sola R, Moreno S, Rockstroh J, et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?. J Med Virol. 2007;79:694–700
  12. Pogany K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses. 2005;21:922–926
  13. Quarleri J, Moretti F, Bouzas M, Laufer N, Carrillo M, Giuliano S, et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-co-infected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007;23:525–531
  14. Piroth L, Lafon M, Binquet C, Bertillon P, Gervais A, Lootvoet E, et al. Occult hepatitis B in HIV–HCV co-infected patients. Scand J Infect Dis, doi:10.1080/00365540801918511.
  15. Re VL, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:315–320
  16. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006;35:14–20
  17. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–1260
  18. Zignego A, Fontana R, Puliti S, Barbagli S, Monti M, Caraccia G, et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol. 1997;142:535–544
  19. Bonino F. Effect of interferon-alpha on progression to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535–1539
  20. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–26
  21. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;12:3529–3536
  22. Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63:220–227
  23. Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio P, Di Marco V, et al. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents. 2003;17:172–175
  24. Fabris P, Brown D, Tositti G, Bozzola L, Giordani M, Bevilacqua P, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol. 2004;29:160–166
  25. Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, et al. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS. 2007;21:2171–2175
  26. Berzsenyi MD, Bowden DS, Kelly HA, Watson KM, Mijch AM, Hammond RA, et al. Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology. 2007;133:1821–1830
  27. Schwarze-Zander C, Blackard JT, Zheng H, Addo MM, Lin W, Robbins GK, et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis. 2006;194:410–419
  28. Christensen PB, Fisker N, Mygind LH, Krarup HB, Wedderkopp N, Varming K, et al. GB virus C epidemiology in Denmark: different routes of transmission in children and low- and high-risk adults. J Med Virol. 2003;70:156–162
  29. Rey D, Fraize S, Vidinic J, Meyer P, Fritsch S, Labouret N, et al. High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus. J Med Virol. 1999;57:75–79
  30. Puig-Basagoiti F, Cabana M, Guilera M, Giménez-Barcons M, Sirera G, Tural C, et al. Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV. J Acquir Immune Defic Syndr. 2000;23:89–94
  31. Lau DT, Miller KD, Detmer J, Kolberg J, Herpin B, Metcalf JA, et al. Hepatitis G virus and human immunodeficiency virus coinfection: response to interferon-alpha therapy. J Infect Dis. 1999;180:1334–1337
  32. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, et al. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. J Clin Microbiol. 2006;44:3105–3113
  33. Tillmann H, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber J, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001;345:715–724
  34. Xiang J, Wunschmann S, Diekema DJ, Klinzman D, Patrick KD, George SL, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med. 2001;345:707–714
  35. Rodriguez B, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis. 2003;187:504–507
  36. Van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JM, et al. GB virus C coinfection and HIV-1 disease progression: the Amsterdam cohort study. J Infect Dis. 2005;191:678–685
  37. Bjorkman P, Flamholc L, Molnegren V, Marshall A, Guner N, Widell A. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. AIDS. 2007;21:1641–1643
  38. Sheng WH, Hung CC, Wu RJ, Wang JT, Chen PJ, Chang SC, et al. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2007;44:584–590
  39. Bjorkman P, Flamholc L, Nauclér A, Molnegren V, Wallmark E, Widell A. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS. 2004;18:877–886
  40. Inoue T, Sakamoto M, Akahane Y, Okamoto H, Miyakawa Y, Mayumi M. Response to interferon of GB virus C and hepatitis C virus in patients with chronic hepatitis. Am J Gastroenterol. 1997;92:1981–1985
  41. Yu M, Chuang W, Dai C, Chen S, Lin Z, Hsieh M, et al. GB virus C/hepatitis G virus infection in chronic hepatitis patients with and without interferon-alpha therapy. Antiviral Res. 2001;52:241–249
  42. Oshita M, Hayashi N, Mita E, Iio S, Hiramatsu N, Hijioka T, et al. GBV-C/HGV infection in chronic hepatitis C patients: its effect on clinical features and interferon therapy. J Med Virol. 1998;55:98–102
  43. Tanaka T, Hess G, Schlueter V, Zdunek D, Tanaka S, Kohara M. Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. J Med Virol. 1999;57:370–375
  44. Williams C, Klinzma D, Yamashita T, Xiang J, Polgreen P, Rinaldo C, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 2004;350:981–990
  45. Umemura T, Alter H, Tanaka E, Orii K, Yeo A, Shih J, et al. SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology. 2002;35:953–959
  46. Sagir A, Adams O, Antakyali M, Oette M, Erhardt A, Heintges T, et al. SEN virus has an adverse effect on the survival of HIV-positive patients. AIDS. 2005;19:1091–1096
  47. Quiros-Roldan E, Torti C, Imberti L, Casari S, Soriano V, Moretti F, et al. SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression. AIDS Res Hum Retrovir. 2003;19:1079–1082
  48. Kao J, Chen W, Chen P, Lai M, Chen D. SEN virus infection in patients with chronic hepatitis C: preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin. J Infect Dis. 2003;187:307–310
  49. Sagir A, Adams O, Kirschberg O, Erhardt A, Heintges T, Haussinger D. SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol. 2004;10:1893–1897
  50. Rigas B, Hasan I, Rehman R, Donahue P, Wittkowski K, Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet. 2001;358:1961–1962

☆ The authors who have taken part in this study declared that they have no relationship with the manufacturers of the drugs involved and did not receive funding from industry to carry out this study.

PII: S0168-8278(08)00429-7

doi: 10.1016/j.jhep.2008.06.024

Journal of Hepatology
Volume 49, Issue 6 , Pages 892-898 , December 2008

Article Tools

* Image Usage & Resolution